Vertex acquires ViaCyte for $320M cash to accelerate T1D stem cell therapy VX-880

VERTEX PHARMACEUTICALS INC / MA

Vertex to acquire ViaCyte for $320 million in cash; ViaCyte becomes wholly owned subsidiary.
Goal is to accelerate development of VX-880, Vertex's investigational stem cell-derived islet therapy for T1D.
ViaCyte brings complementary tools: stem cell lines, IP, GMP manufacturing, and hypoimmune assets via CRISPR collaboration.
Acquisition expected to close later this year, subject to HSR waiting period and other customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.